Lee Joung Hee, Engler Marguerite M
Department of Physiological Nursing, School of Nursing, University of California, San Francisco, CA 94143-0610, USA.
Prog Cardiovasc Nurs. 2009 Dec;24(4):181-9. doi: 10.1111/j.1751-7117.2009.00057.x.
Atherosclerosis is an inflammatory disease that can be assessed by circulating biomarkers. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an enzyme produced in atherosclerotic plaque and is bound to low density lipoprotein and high-density lipoprotein cholesterol. It has a role in the pathogenesis of atherosclerosis by promoting vascular inflammation. It is emerging as a vascular-specific marker and predictor of risk for cardiovascular disease (CVD) events. Increasing evidence from many prospective epidemiologic studies have shown that elevated levels of Lp-PLA(2) are associated with future CVD events. Measurement of Lp-PLA(2) in individuals may provide clinically relevant information about their future risk of CVD events. Pharmacologic therapies and/or risk factor modification could be initiated after identification of individuals at risk for CVD. This review provides an overview of the pathophysiology, epidemiologic evidence, and clinical utility of Lp-PLA(2).
动脉粥样硬化是一种可通过循环生物标志物进行评估的炎症性疾病。脂蛋白相关磷脂酶A2（Lp-PLA2）是一种在动脉粥样硬化斑块中产生的酶，与低密度脂蛋白和高密度脂蛋白胆固醇结合。它通过促进血管炎症在动脉粥样硬化的发病机制中发挥作用。它正成为一种血管特异性标志物和心血管疾病（CVD）事件风险的预测指标。许多前瞻性流行病学研究的证据越来越多地表明，Lp-PLA2水平升高与未来的CVD事件相关。对个体进行Lp-PLA2检测可能会提供有关其未来CVD事件风险的临床相关信息。在识别出有CVD风险的个体后，可以启动药物治疗和/或风险因素调整。本综述概述了Lp-PLA2的病理生理学、流行病学证据和临床应用。
